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Abstract 
Modafinil is a wakefulness-promoting drug that is becoming more commonly used for off-
label for attentional enhancement in healthy individuals despite conflicting evidence to 
support this. The aim of the current study was to investigate the effects of modafinil on 
behavioural (reaction time & accuracy) and ERP (N1 amplitude) measures of the attentional 
alerting and orienting networks and also investigate any sex differences associated with these 
effects. The final sample consisted of 14 females and 22 males who were all healthy and met 
the screening criteria. Each participant completed two sessions differing by drug condition 
(200mg modafinil or placebo). The Attentional Network Task was used to assess the effects 
on both the alerting and orienting network and this task was completed at baseline and at 2.5 
hours post-ingestion. As expected, reaction time decreased and N1 amplitude increased as 
cues became more informative. There was a small enhancement of the alerting network 
demonstrated by a significant decrease in reaction time from baseline to post-ingestion for 
central cues in the modafinil condition but not placebo. There was a small significant 
decrease in reaction time from baseline to post-ingestion for spatial cues but this is likely due 
to alerting enhancement rather than orienting as the effects were of similar size. Inconsistent 
to the hypotheses, males had a faster reaction time to all cue types when compared to 
females. Males also showed greater N1 amplitude after modafinil ingestion than placebo, 
indicating some sex differences in the effect of modafinil may be present. These results 
suggest that modafinil may have an enhancing effect on the alerting network but not the 
orienting network. The effects of modafinil on the orienting network has not been well 
studied so future research is required to confirm this finding. There also appears to be 
differential effects of modafinil on males and females, which also requires future 
investigation as this is the first study to look at these effects.  
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Modafinil is a schedule IV drug labelled as a psychostimulant for its wakefulness 
promoting properties (Minzenburg & Carter, 2008). It is most commonly used to treat 
excessive daytime sleepiness in narcolepsy, shift work disorder and obstructive sleep apnoea. 
However, it is becoming more commonly used off-label for a variety of other conditions 
including attention-deficit/hyperactivity disorder (ADHD) and depression.  
Modafinil has also been evaluated for cognitive enhancement (including attention) in 
healthy individuals. Petersen and Posner (2012) suggest three main networks of attention, 
alerting, orienting and executive control. Findings into the effects of modafinil on these 
networks have been inconsistent. When methodological issues are accounted for (task 
complexity), there are consistent findings of alerting network enhancement after modafinil 
ingestion, but only for complex task paradigms (Battleday & Brem, 2015). The orienting 
network has not been extensively studied, with only one study using a task that could analyse 
orienting (Ikeda, Funayama, Tateno, Fukayama, Okubo, & Suzuki, 2017). This study did not 
find any orienting enhancement after modafinil ingestion, but further research is required into 
the effect of modafinil on this network. Similarly to the alerting network, research suggests 
that more complex task paradigms (including inhibitory control processes) are required to 
detect enhancement after modafinil in executive control components of attention (Battleday 
& Brem, 2015).  
There is evidence that males and females differ in the attentional networks. 
Specifically, females appear to be better at orienting their attention (orienting network) and 
responding to valid cues while males show less costs to invalid cues (Liu, Hu, Fan, Wang, 
2013; Merritt, Hirshman, Wharton, Stangl, Devlin & Lenz, 2007. With regards to Event-
Related Potential (ERP) indices of attentional processes, females have shown greater N1 
amplitude while completing orienting based tasks than males. However, no study is yet to 
investigate the differing effects of modafinil on males and females attentional processing. 
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Most studies examining the effects of modafinil have recruited exclusively male participants, 
while studies that do incorporate females have failed to analyse for any sex differences. 
Therefore, this study aims to investigate the effects of modafinil on both males and females 
attention, by using an attentional network task to specifically assess Petersen and Posner 
(2012)’s alerting and orienting networks.   
Neurochemical Effects of Modafinil 
 Modafinil is a wakefulness-promoting agent primarily prescribed for the treatment of 
narcolepsy and excessive daytime sleepiness, but is becoming more commonly used for other 
conditions (Minzenburg & Carter, 2008). It is a psychostimulant, but has been found to 
contain a different structure to other amphetamines. Modafinil has various effects on the 
catecholamine system, including reuptake inhibition of dopamine and norepinephrine as well 
as increased levels of serotonin, glutamate and catecholamine and decreased GABA. 
Dopamine receptors are thought to be crucial for the arousal and wakefulness effects of 
modafinil (Qu, Huang, Xu, Matsumoto & Urade, 2008), as are the effects on the 
catecholamine systems (Minzerburg & Carter, 2008). 
The Attentional Networks 
Attention is an important aspect of cognitive functioning as it allows the brain to sift 
through vast amounts of information that is received through the senses (Einother & 
Guesbrecht, 2013). Petersen and Posner’s (2012) attentional model outlines three separate but 
interacting networks of attention, alerting, orienting and executive control.  
The alerting network is involved in maintaining arousal and vigilance when 
completing a task (Petersen & Posner, 2012). To analyse the alerting network, a warning 
signal is produced prior to the onset of the target, which replaces the resting state with a state 
of readiness for the target to appear. This measures phasic alertness. Another way to measure 
alerting is to use a long task to measure sustained vigilance or tonic alertness. The alerting 
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network primarily relies on the neurotransmitter norepinephrine (Petersen & Posner, 2012). 
The brain areas involved include the locus coeruleus, as well as regions of the frontal and 
parietal cortices. As norepinephrine is increased in the brain after modafinil ingestion 
(Petersen & Posner, 2012), it could be expected to enhance the alerting network. 
The orienting network is involved in prioritising certain sensory information by 
selecting it amongst other sensory information (Petersen & Posner, 2012). The frontal and 
parietal areas are primarily involved in the orienting network. There are two brain systems 
relating to the orienting network, a dorsal system and a ventral system (Vossel, Geng & Fink, 
2014). The dorsal system is comprised of the intraparietal sulcus and the frontal eye fields of 
each hemisphere, which are organised retinotopically. The dorsal system is active when 
attention is covertly or overtly oriented in space, such as after a predictive spatial cue. The 
ventral system is made up of the temporoparietal junction and the ventral frontal cortex. This 
system is activated when stimuli appear in an unexpected location such as when an invalid 
cue is presented and is involved in disengaging attention from the current location.   
 The executive control network is involved in higher order processes including 
selective attention and monitoring of stimuli (Petersen & Posner, 2012). This network 
consists largely of the anterior cingulate cortex and frontal brain areas. The primary 
neurotransmitter is the dopamine neurotransmitter. Executive control relies on top down 
control processes and performance guidance signals. As dopamine is increased by modafinil, 
it could be expected to enhance the executive control network.  
The Attentional Network Task 
The attentional network task is a paradigm designed to analyse the alerting, orienting 
and executive control networks (Fan, McCandliss, Sommer, Raz & Posner, 2002). In the task, 
one of three different cue types is presented before the target appears. These are no cue 
(continue to see fixation cross), a central cue (cue appears over fixation cross) and a spatial 
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cue (cue appears either above or below the fixation cross). The central cue is thought to 
activate the alerting network, as a state of alertness is elicited by the cue. The spatial cue is 
always valid (appears at the same location as the target) and activates the orienting network, 
as the cue guides the participant’s attention to the location the target will appear. The target is 
an arrow (appearing above or below fixation), facing to the left or the right, which is 
accompanied by four flanker arrows, two on each side. The flanker arrows are either 
congruent (facing the same way as the target) or incongruent (facing the opposite way to the 
target). These flanker arrows assess the executive control network, as incongruent arrows 
must be inhibited to respond to the target, which is facing the opposite way. Participants 
respond to the direction of the centre arrow by pressing the corresponding button.  
Neuhaus et al. (2010) investigated the alerting, orienting and executive control 
networks using the attentional network task. The results indicate that reaction time was 
significantly faster following central cues than no cue, which indicates activation of the 
alerting network. Reaction time was also significantly faster following spatial cues relative to 
central cues, which indicates activation of the orienting network.  
Electrophysiological correlates of the ANT 
 Event-related potentials (ERPs) involve placing electrodes on the scalp to record brain 
activity and then averaging that activity to a specific target (Luck, 2014). ERPs can be used 
to determine specific neural mechanisms of attention. The visual N1 component peaks 
approximately 150ms post stimulus and is influenced by spatial attention. The N1 component 
appears larger (more negative) when participants are required to discriminate between stimuli 
than when they are merely required to detect the presence of a stimulus (Vogel & Luck, 
2000). The N1 component is greater when the spatial scale of attention is more focussed (e.g. 
smaller cues) (Matthews, & Martin, 2015).  
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 Neuhaus et al (2010) also analysed the target locked N1 component following each 
cue type in the attentional network task. The results showed that N1 amplitude was 
significantly greater for central cues compared to no cues. N1 amplitude was also 
significantly greater following spatial cues relative to central cues. This indicates that the N1 
component becomes greater (more negative) as cues become more informative.  
Sex Differences and Attentional Networks 
 The research into sex differences in the attentional networks has produced mixed 
findings. Consistently, there have been no significant differences found between males and 
females for the alerting and executive control networks (Liu et al. 2013; Neuhaus et al. 2009; 
Xiao et al. 2016). The findings for the orienting network are more inconclusive, with some 
studies reporting differences between males and females and others reporting no difference.  
 Several studies have used an attentional network task to examine sex differences for 
the orienting network. Liu et al. (2013) used this paradigm and their results showed an 
increased orienting effect in females when compared to males. This result indicated that 
females were better at orienting their attention to the target than males. Another study used 
the attentional network task to determine any sex differences in the orienting network (Xiao 
et al., 2016). This study reported no significant differences between males and females for 
spatial cues, indicating no difference in the orienting network between the sexes. There were 
also no significant differences in alerting or executive control between females and males.  
 Neuhaus et al. (2009) also used an attentional network task to see if any sex 
differences are present in the orienting network. This study used reaction time measures as 
well as event related potentials, including the N1 component. The results showed a trend 
towards males having a faster reaction time, but this difference was not significant. However, 
there was a significant difference in the N1 component for spatially cued trials between the 
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sexes. Females showed a second N1 component peak, which resulted in greater N1 activity in 
females than in males.  
 An additional study used a spatial cuing paradigm to analyse sex differences in the 
orienting network (Merritt et al. 2007). This task required participants to respond to a target 
that appeared in one of four boxes on the screen. Some targets were preceded by cues, some 
were valid and some were invalid. The findings showed that males had a reduced overall 
reaction time when compared to females. More specifically, males showed a benefit from the 
invalid cues compared to the no cue control trials, while females showed benefit from the 
valid cues. As cues in the attentional network task are always valid, this finding could be 
consistent with the results of Liu et al. (2013), such that females indicated an increased 
orienting effect when compared to males. As females were found to benefit from valid cues, 
this could indicate why females were found to be better with spatial cues on the attentional 
network task. 
 The research into sex differences in the attentional networks has produced mixed 
results. Consistently, no effect has been found for either the alerting or executive control 
networks. However, the research is inconsistent into the differences between males and 
females for the orienting network. Significant findings suggest that females perform better on 
orienting tasks than males and also have greater N1 amplitude, however, more research is 
needed to corroborate these findings. There is currently no research into the effect of 
modafinil on these sex differences. 
Modafinil and Attention 
Repantis, Schlattmann, Laisney and Heuser (2010) conducted a review of the 
literature surrounding the effect of modafinil on attentional processes in healthy non-sleep 
deprived individuals. The review included 25 previous articles that specifically used 
modafinil to investigate the effects on attention. In studies where modafinil was only 
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administered once, non-sleep deprived individuals showed a moderate positive improvement 
in attention following modafinil ingestion (d=0.56). The tasks employed by the reviewed 
studies primarily assessed the alerting network (reaction time tasks, digit detection tasks, 
rapid visual information processing task). The executive control network could not be 
analysed in this review due to the lack of baseline data. 
Battleday and Brem (2015) conducted a later review of the literature concerning 
modafinil and attention in healthy individuals. This review included 24 studies. The results 
found no consistent improvement to simple attention tasks (reaction time tasks, Rapid Visual 
Information Processing Task) following modafinil. However, when more complex tasks were 
used to analyse attention, more consistent improvements are observed. These tasks primarily 
assessed more than one cognitive domain (learning task involving attention, decision making 
based on spatial targets). The inconsistent results for studies using simple tasks could be due 
to those tasks lacking the sensitivity to detect any attentional differences in healthy non-sleep 
deprived individuals. Therefore, it is suggested that more complex tasks should be used when 
assessing healthy individuals to address the ceiling effects observed for simple tasks.  
Battleday and Brem (2015) found enhancement of inhibitory control in studies that 
used a more complex task. The findings into the effects of modafinil on executive functions 
for simple tasks are inconsistent, with some studies reporting significant differences and 
others reporting null findings. This suggests that more complex tasks (tasks presenting 
stimuli visually and auditory simultaneously) may be necessary to detect enhancement of 
inhibitory control after modafinil ingestion.   
The Alerting Network and Modafinil 
 The research into the effects of modafinil on the alerting network has produced 
varying results. These inconsistencies could be due to the methodological issues, mainly 
ceiling effects that have been identified when simple tasks are used to assess the alerting 
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network (Battleday & Brem, 2015). Turner et al. (2003) used the RVIP to assess sustained 
attention. This task was part of a larger cognitive battery. The RVIP involves detecting a 
series of three digits from a sequence of consecutively presented digits. Sixty participants 
were allocated to either a placebo, 100mg modafinil or 200mg modafinil condition and 
completed the cognitive battery two hours post drug ingestion. The results indicated no 
difference between any of the conditions in their reaction time, suggesting no enhancement of 
the alerting network.  
 Randall, Shneerson and File (2005) also used the RVIP to assess sustained attention. 
Eighty-nine healthy non-sleep deprived participants completed one session where they 
received either 100mg modafinil, 200mg modafinil or a placebo. Participants were also split 
into low IQ and high IQ groups using their scores on the National Adult Reading Test-II. The 
RVIP was part of a larger cognitive battery and was completed 2-3 hours post-ingestion. The 
results showed modafinil significantly decreased the number of missed targets. Target 
sensitivity was significantly higher in both modafinil conditions but this was only present in 
the low IQ group. These results suggest that in high IQ samples, some tasks may not be 
sensitive enough to detect the effects of modafinil.  
 Liepert, Allstadt-Schmitz, and Weiller (2004) used a reaction time task that evoked 
both phasic and tonic alertness to investigate the effect of modafinil on the alerting network. 
Ten male participants completed two sessions at least two weeks apart where they either 
ingested 200mg modafinil or placebo. For each session testing occurred 1 hour prior to 
ingestion, 2-3 hours after ingestion, and 24 hours later. The reaction time task involved a 
visual go-signal in which the participants responded by pressing a button (tonic alertness). 
Some trials were preceded by an auditory warning signal (phasic alertness). While the 
reaction time was generally faster for trials with the warning cue than those without, there 
was no significant difference between conditions on their reaction times for the task. These 
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results indicate no enhancement of the alerting network after modafinil ingestion. This could 
be because the task used in this study along with the RVIP used by Turner et al. (2003) and 
Randall et al. (2005) were not sensitive enough to detect a difference between the modafinil 
and placebo groups in a healthy non-sleep deprived population.  
 Theunissen et al. (2009) used a more complex task to assess the alerting network after 
modafinil ingestion. A sustained attention Mackworth clock test was used which includes a 
clockwise sequence of dots that light up. Participants have to respond by pressing a button 
when one of the dots was missed in the sequence. Sixteen participants (11 female) completed 
two sessions, one 200mg modafinil session and one placebo session. The clock test was 
completed as part of an array of other tasks and testing occurred two hours after ingestion. 
Reaction time was significantly lower in the modafinil condition when compared to placebo, 
indicating that modafinil enhanced the alerting network. There was no treatment effect on 
accuracy.  
Cope et al. (2017) investigated the effects of a single dose of modafinil (200mg, 
400mg or placebo) on the alerting network. Sixty healthy participants were allocated to one 
of the three conditions where they completed the 5-choice continuous performance task after 
drug ingestion. The task involved participants moving a joystick in the direction of a white 
dot that appeared behind one of five white lines, or not responding if dots appeared behind all 
of the five white lines (no-go trials). Both doses of modafinil enhanced performance on this 
task. The improvement in this task was possibly a result of more targets detected by both 
modafinil doses than placebo, leading to higher accuracy. This suggests that modafinil 
enhanced the alerting network by increased ability to detect targets in the task.   
Baranski, Pigeau, Dinich, and Jacobs (2004) assessed the effects of modafinil on the 
alerting network as part of a larger cognitive battery. Eighteen male participants completed 
testing at three time points throughout each session (90 minutes prior to ingestion, 90 minutes 
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after ingestion and three hours after ingestion). Two sessions were completed and differed by 
drug condition, 4mg/kg of modafinil or placebo. The detection of repeated numbers task was 
used to measure sustained attention. The task consists of three numbers presented on a screen 
simultaneously, and requires participants to respond when the same three-digit sequence 
occurs twice in a row. Modafinil resulted in increased vigilance on the task but it was due to 
more targets being detected in the modafinil condition, leading to a higher accuracy. This is 
consistent with the findings by Cope et al. (2017) where modafinil ingestion resulted in 
increased accuracy when compared with placebo.  
 Ikeda et al. (2017) assessed the alerting network using an attentional network task. 
The task was adapted for use with fMRI so brain activation could be analysed. The study 
included 23 participants (14 male) who each completed two sessions at least two weeks apart 
in which they completed both a placebo and 200mg modafinil. The participants completed 
the attentional network task at 2.5 hours post drug ingestion. The reaction time for the 
modafinil condition was significantly faster for central cue trials when compared with the 
placebo condition, indicating enhancement of the alerting network. The alerting effect was 
calculated by subtracting the mean reaction time for the central cue trials from the mean 
reaction time for the no cue trials, which produced no treatment difference of the alerting 
effect between modafinil and placebo conditions. The accuracy of the task was higher in the 
modafinil condition. For fMRI analyses, the modafinil condition showed significantly more 
activation in certain areas, particularly the occipital gyri, than the placebo condition. These 
results suggest that the alerting network was enhanced after modafinil ingestion.  
 In summary, when more complex tasks (clock test, detection of repeated numbers, 
attentional network task) are used to investigate the effects of modafinil on the alerting 
network the results are more consistent. These tasks appear to be more sensitive in detecting 
differences between modafinil and placebo conditions in healthy populations (Baranski et al. 
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2004; Cope et al. 2017; Ikeda et al. 2017; Theunissen et al. 2009). The same result could be 
expected in the present study, using an attentional network task to investigate the effect of 
modafinil on the alerting network. If consistent with these studies, the alerting network 
should be enhanced after modafinil ingestion. 
 The Orienting Network and Modafinil 
 There is currently only one study that has investigated the effects of modafinil on the 
orienting network. As mentioned above, Ikeda et al. (2017) used an attentional network task 
to investigate the effect of 200mg of modafinil as well as a placebo dose on the orienting 
network. The task was adapted for use with fMRI. The behavioural results were obtained by 
subtracting mean reaction time for the spatial cue trials from the mean reaction time for the 
central cue trials. This showed that modafinil did not enhance the orienting network when 
compared with the placebo condition. However, the accuracy for the task was higher in the 
modafinil condition when compared with the placebo condition. There were no significant 
differences in brain activation between the modafinil and placebo conditions as shown by the 
fMRI analyses. These results suggest that modafinil does not enhance the orienting network. 
The same result could be expected for the orienting network in a study using the same dose of 
modafinil and also an attentional network task. 
Aim, and Hypotheses 
 There are currently no studies that investigate the differential effect of modafinil on 
attentional processing of males and females. This study aims to address this gap in the 
literature by recruiting both male and female participants and directly analysing for any sex 
differences after modafinil ingestion compared to placebo. There are also no studies that use 
ERP measures to investigate the effect of modafinil on the N1 component. This study will 
include the N1 component as a dependent measure to address this.  
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 The aim of this study is to investigate the effect of 200mg modafinil on attentional 
alerting and orienting networks and investigate any sex differences associated with these 
effects. The executive control network will not be analysed as it is out of the scope of this 
thesis. Reaction time, accuracy and N1 amplitude will be the dependent measures used.  
 Consistent with Neuhaus et al. (2010) it is hypothesised that reaction time will be 
significantly shorter following central cue trials than no cue trials. Reaction time should also 
be significantly shorter following spatial cue trials than central cue trials. As it is expected 
that modafinil will enhance the alerting network, the difference in reaction time between the 
central cued trials and the no cued trials should be greater in the modafinil condition 
compared to the placebo condition. It is not expected that modafinil will enhance the 
orienting network, therefore the difference in reaction time between the spatial cued trials and 
the central cued trials will not be significantly different for the modafinil and placebo 
conditions.  
 The N1 component is expected to be significantly larger (more negative) following 
central cue trials than no cue trials. The N1 will also be significantly greater following spatial 
cue trials compared to central cue trials. As alerting enhancement after modafinil is expected, 
the difference in N1 amplitude between the central cued trials and the no cued trials will be 
larger in the modafinil condition compared to the placebo condition. As no orienting 
enhancement is expected, the difference in N1 amplitude between the spatially cued trials and 
the central cued trials will be consistent for both the modafinil and placebo conditions.  
 It is not expected that reaction time or N1 amplitude will be significantly different for 
male and females following central cue trials or no cued trials. Therefore, it is not expected 
that males and females will show any significant differences in these measures after 
modafinil ingestion. Consistent with findings by Liu et al. (2013) it is expected that females 
will have a significantly faster reaction time following spatial cues than males. Females will 
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also show greater N1 amplitude following spatial cues than males. As it is not expected that 
modafinil will directly influence the orienting network, males and females should not differ 
significantly between the modafinil and placebo doses.  
Method 
Participants 
An a priori power analysis indicated that 20 participants per group would be required 
to detect a moderate effect (f=0.25) with a power of 0.8. The final sample consisted of 14 
females and 22 males aged 18-30 (M=21.38, SD=2.89). Recruitment occurred through the 
university resources and via social media. Participants were excluded if they smoked 
nicotine, frequently used illicit drugs, were not in the 18-30 age range or were taking any 
medications. Participants were also excluded if they were at high risk of alcohol dependence, 
identified by scores >16 on the Alcohol Use and Disorders Identification Test (AUDIT) 
(Babor, Higgins-Biddle, Saunders & Monteiro, 2001). Participants were excluded if they 
were at high risk of psychological distress as measured by scores <30 on the Kessler 
Psychological Distress Scale (K10) (Andrews & Slade, 2001) or if they were at risk of 
psychosis as measured by scores >1 on the Psychosis Screener (Degenhardt, Hall, Korten, 
Jablensky, 2005) and scores >17 on the Schizotypal Personality Questionnaire-Brief (Raine 
& Benishay, 1995). Participants received $80 as reimbursement for their time and first year 
psychology students could receive 4 hours course credit and $40.  
Materials and Apparatus 
Screening Questionnaires 
The Alcohol Use and Disorders Identification Test (AUDIT). The AUDIT is a 
measure of alcohol abuse and dependence (Babor et al. 2001). It is comprised of three items 
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assessing hazardous alcohol use, three items assessing dependence symptoms of alcohol and 
four questions assessing harmful alcohol use. The first eight questions are responded to on a 
five-point scale and the last two are on a three-point scale.  Scores greater than 16 are 
indicative of problematic alcohol use or dependence.  
The Kessler Psychological Distress Scale (K10).  The K10 is a measure of global 
psychological distress (Andrews & Slade 2001). The scale is comprised of ten questions 
about how the individual has been feeling over the past four weeks. Response is on a five-
point scale from 1 (none of the time) to 5 (all of the time). Scores higher than 30 are 
considered to be at high risk of psychological distress.  
Psychosis Screener. The psychosis screener consists of four items plus three sub-
items that measure an individual’s risk for psychosis (Degenhardt et al. 2005). The questions 
are related to the main symptoms experienced by those with psychosis and are responded to 
with either a yes or no answer.  
Schizotypal Personality Questionnaire-Brief (SPQ-B). The SPQ-B consists of 22 
items that measure for schizotypal personality traits (Raine & Benishay, 1995). Items are 
answered either true or false and fall within three categories (cognitive-perceptual, 
disorganised and interpersonal). Scores >17 indicate high schizotypy.  
Demographic Questionnaires 
The Wechsler Test of Adult Reading (WTAR). The WTAR is a measure of verbal 
intelligence (Green et al. 2008). It is made up of fifty irregular words that the participant is 
asked to read aloud. For each correct word, a point is given, with higher scores indicating 
higher intelligence. Raw scores can then be converted to standard scores to give an estimate 
of verbal IQ. 
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Wakefulness and Affect Measures 
Karolinska Sleepiness Scale (KSS). The KSS is a measure of present fatigue and 
sleepiness (Akerstedt & Gillberg, 1990). Participants rate their fatigue on a nine-point scale 
ranging from 1 (extremely alert) to 9 (very sleepy, fighting sleep). 
Profile of Mood States- Short Form (POMS-SF). The POMS-SF is a measure of 
subjective mood (Shacham, 1983). It is comprised of 37 different mood states, which 
participants rate for their present feeling of that state. Responses are given on a five-point 
scale, ranging from 0 (not at all) to 4 (extremely).  
Visual Analogue Scales (VAS). VAS were used as measures of subjective 
performance and subjective drug effects. The VAS comprised of four statements regarding 
perceived performance at the present time and four statements regarding feeling the effects of 
the drug at the present time. Participants mark the point on a 10cm line that most accurately 
describes their experience at the time from ‘strongly agree’ to ‘strongly disagree’. The line 
was measured and converted to a percentage out of 100%. VAS subjective performance 
statements included alertness, ability to perform tasks, impaired driving, and capacity to drive 
safely at the time. For statements about subjective drug effects, statements related to liking of 
the drug, strength of the drug, alert level and intoxication.  
Attentional Network Task 
The attentional network task was based on the version developed by Fan et al. (2002) 
(See Figure 1). The task began with ten practice trials. The baseline task consisted of 192 
trials that lasted approximately 10 minutes in total. The experimental task consisted of 586 
trials that were randomly generated lasting approximately 35 minutes. Instructions appeared 
on the screen prior to the start of the task that indicated what should be responded to, and 
which buttons to press. A white fixation cross appeared on the screen throughout the duration 
of the task. The task begins with 400ms of fixation, followed by presentation of one of three 
17 
 
 
 
cue types for 100ms. For the central cue, the cue appeared over the fixation cross. For the 
spatial cue, the cue appeared 1.01 degrees either above or below the fixation cross. Spatial 
cues were always valid and indicated the location that the target would appear. After the cue, 
the target was presented. This was an arrow, which was facing either to the left or the right. 
The target arrow was accompanied by four flanker arrows, two on each side, which were 
either congruent (>>>>>) or incongruent (<<><<) with the target arrow. The participant’s 
task was to respond to the direction of the target arrow by pressing the corresponding button 
as quickly and accurately as possible. The response was collected between 150-1500ms after 
the target was presented. The task had four inter-trial intervals, 1,300ms, 1,200ms, 1,100ms 
and 1,000ms.  
 
 
Figure 1. An Illustration of the Attentional Network Task 
Electrophysiological Recording 
A NeuroSCAN system and a 32-channel Quik cap was used to record 
electrophysiological (EEG) activity. EEG data was recorded continuously from 32 electrode 
sites using the 10-20 system of electrode placement. Electrodes were referenced to the 
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mastoids and impedance was kept below 10kΩ. Electro-oculographic activity was recorded 
horizontally from electrodes placed outside the eyes and vertically with electrodes placed 
above and below the eye.  
The behavioural and ERP data were merged together for editing. Data was filtered 
through a low pass filter (30Hz, 24dB/Oct). Ocular artefact reduction was used to reduce 
interference from eye blinks. Epochs were extracted from -100-900ms post stimulus and an 
artefact rejection procedure was applied at -/+ 70 microvolts.  
Procedure 
 The University of Tasmania Health and Medical Human Research Ethics Committee 
approved the study (H0011386, Appendix A). Participants gave informed consent before 
beginning their first session (Appendix B, C & D). Screening interviews were conducted over 
the phone and consisted of questions relating to age, previous illicit drug use, medical history 
and smoking status as well as short versions of the AUDIT and the Psychosis Screener 
(Appendix E). Additional screening questions were completed at the beginning of the first 
session and included the full AUDIT, K10 and SPQ-B (Appendix F).  
 Eligible participants completed two four-hour sessions that were at least a week apart 
to ensure no lasting effect of modafinil. These sessions differed by drug condition (200mg 
modafinil or placebo capsules made with cornflour). This was double-blind and randomised. 
All sessions began at either 12 or 1pm. Participants were instructed to abstain from alcohol 
24 hours prior to each session, maintain normal caffeine intake, abstain from 
paracetamol/ibuprofen on the day and eat a light meal before the session. Researchers were 
first aid trained in case of any adverse reactions to the modafinil. 
 At the beginning of session 1, participants completed demographic questions as well 
as the full AUDIT, K10, SPQ-B and WTAR. For both sessions, participants completed 
questionnaires relating to food and caffeine intake for that day as well as the POMS-SF, KSS 
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and VAS for subjective performance (Appendix F). Pre-ingestion, participants completed the 
baseline versions of two tasks (25 minutes total), including the ANT. Participants then 
consumed the capsules and waited for approximately 2 hours. They were then set up for 
electrophysiological recording and were ready to complete the full experimental tasks, 
including the ANT at 2.5 post-ingestion. These tasks lasted a combined total of 45 minutes 
and order was counterbalanced across participants. After completing both tasks, participants 
completed additional questionnaire measures (POMS-SF, KSS, and both VAS measures). 
Participants also indicated as a percentage the likelihood that they believed they had ingested 
the modafinil capsules in the current session. The second session followed the same design as 
the first, only differing in capsule content. At the end of the second session, participants were 
debriefed, thanked for their time and reimbursed with AUD$80 or a combination of cash and 
course credit (for first year psychology students). 
Design and Data Analysis 
 Two separate 3x2x2x2 repeated measures ANOVAs were conducted to examine the 
effects of Cue (no, central, spatial), Drug (modafinil or placebo), Time (baseline or post-
ingestion) and Sex (female, male) on reaction time and accuracy. As congruency was not of 
particular interest to the current study, the data was averaged across congruent and 
incongruent trials. Pairwise comparisons were used to follow up significant interactions. 
Non-significant interactions that were relevant to the hypotheses were followed up with 
hypothesis driven planned comparisons.  
 The dependent measure of N1 amplitude was maximal at electrode site OZ as 
determined by preliminary analyses, and all further analyses were restricted to this electrode 
site. A third 3x2x2 repeated measures ANOVA was conducted with the variable of Time 
removed, as ERP data was only collected post-ingestion. Similarly, significant interactions 
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were followed up with pairwise comparisons and any hypothesis related interactions were 
followed up with hypothesis driven planned comparisons.  
 Paired-samples t-tests were used to determine any differences in control variables at 
baseline for each session (caffeine, sleep hours, fatigue, alertness). Paired-sample t-tests were 
also used to measure whether VAS subjective drug effects (alertness, liking of drug, strength 
of drug and intoxication) differed at post-ingestion between drug conditions.  
 Four 2x2x2 repeated measures ANOVAs were used to analyse the effect of Time, 
Drug and Sex on VAS subjective performance ratings (alertness, task ability, impaired 
driving and drive safely. Six 2x2x2 repeated measures ANOVAs were conducted for each 
POMS subscale (total, depression-dejection, vigour-activity, fatigue-inertia, tension-anxiety, 
anger-hostility and confusion-bewilderment) by Drug, Time and Sex. A 2x2x2 repeated 
measures ANOVA was conducted for the KSS by Drug, Time and Sex.  
 For all main effects and interactions involving the variable Cue, sphericity was not 
assumed as there are three levels and therefore a Greenhouse-Geisser correction was made 
for all the relevant analyses. Partial eta squared was used to quantify effect sizes for all 
ANOVAs and Hedge’s g was used to aid in the interpretation of any planned comparisons 
and was interpreted using Cohen’s (1992) guidelines, small (0.2), moderate (0.5) and large 
(0.8). 
Results 
Demographic and Screening Measures 
 Participants scored within the cut off limits on all screening variables, with no one 
displaying any problematic alcohol use, risk of psychosis or risk of psychological distress 
(Table 1). All participants had completed to at least year 10 and most were enrolled at 
University (79.1%) at time of testing. BMI was within the normal range and mean 
intelligence was above average for this age group. 
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Table 1 
Means for Demographic and Screening Variables 
 Female Male 
Variable M (SD) Range M (SD) Range 
Age 21.25 (3.57) 19-30 21.46 (2.54) 19-27 
K10 12.13 (3.25) 5-18 12.67 (4.53) 8-23 
AUDIT 6.40 (4.30) 0-15 4.05 (2.80) 0-10 
WTAR (standard score) 112.00 (10.45) 87-124 104.50 (9.72) 80-119 
BMI 24.99 (3.48) 17-31 23.01 (3.88) 18-34 
 
Manipulation Check 
A paired samples t-test revealed that participants were more sure that they had taken 
modafinil in the modafinil condition (M=55.54, SD=34.49) than the placebo condition 
(M=28.24, SD=30.09), t(34)= 3.76, p=.001, g=0.83.  
Baseline 
A series of paired sample t-tests revealed that participants did not differ significantly at the 
baseline of each session for possible confounding variables (Table 2). Participants did not 
differ in the number of caffeinated beverages consumed before each session and hours of 
sleep were consistent across both sessions. Baseline reports of fatigue (KSS), Alertness 
(VAS) and mood (POMS) were not significantly different across sessions.  
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Table 2  
Means (SD) & t-test results for Baseline Measures 
 Modafinil Placebo t p g 
Caffeine Intake 0.68 (0.82) 0.65 (0.72) 0.27 .786 0.04 
Sleep (hours) 7.61 (1.10) 7.88 (1.13) -1.44 .158 -0.24 
Fatigue (KSS) 4.41 (1.52) 4.32 (1.40) 0.36 .723 0.06 
Alertness (VAS) 32.39 (13.53) 34.53 (17.30) -0.94 .353 -0.14 
Total Mood 
Disturbance (POMS) 
12.81 (9.14) 13.03 (8.31) -0.20 .842 -0.03 
 
Mood and Fatigue 
 There were significant Time x Drug interactions for the depression-dejection, vigour-
activity and fatigue-inertia subscales of the POMS (Tables 3 & 4). Planned comparisons 
revealed depression-dejection was significantly decreased from baseline to post-ingestion in 
the modafinil condition (p=.003, g=0.69). Fatigue-inertia was significantly higher from 
baseline to post ingestion for the placebo condition (p<.001, g=0.93), with no differences for 
the modafinil condition. Vigour-activity was significantly lower from baseline to post-
ingestion in the placebo condition (p<.001, g=1.07), with no differences in the modafinil 
condition. There was no significant Time x Drug x Sex interactions for any of the POMS 
subscales. 
 There was a significant Time x Drug interaction for the KSS. Planned comparisons 
revealed a significant increase in fatigue from baseline to post-ingestion for the placebo 
condition (p=.004, g=0.65). The Time x Drug x Sex interaction for the KSS was not 
significant.  
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Table 3 
Means for Mood (POMS), Fatigue (KSS) and Subjective Performance (VAS) Measures 
 Modafinil Placebo 
Measures Baseline Post Ingestion Baseline Post Ingestion 
POMS measures:     
  Total score 12.2 (9.1) 13.0 (8.3) 12.4 (10.3) 13.2 (11.7) 
  Tension-Anxiety 1.73 (2.9) 1.49 (2.3) 1.68 (3.4) 1.24 (2.2) 
  Depression-Dejection 0.84 (1.9) 0.51 (1.1) 0.03 (0.2) 1.05 (2.9) 
  Anger-Hostility 0.16 (0.9) 0.08 (0.3) 0.11 (0.4) 0.43 (1.2) 
  Vigour-Activity 6.49 (5.0) 7.43 (4.5) 7.00 (5.9) 3.76 (3.1) 
  Fatigue-Inertia 2.38 (2.4) 2.16 (2.3) 2.60 (3.1) 5.11 (4.5) 
  Confusion-Bewilderment 1.22 (1.7) 1.32 (2.4) 0.97 (2.2) 1.60 (2.7) 
KSS 4.47 (1.5) 4.39 (1.4) 3.92 (1.8) 5.39 (1.9) 
VAS Performance 
measures: 
    
   Alert 32.4(13.5) 9.5 (17.93) 21.1 (12.2) 6.75 (14.1) 
   Task Ability 24.5 (20.4) 18.9 (22.3) 21.1 (19.8) 17.3 (23.4) 
   Impaired Driving 34.5 (17.3) 10.8 (17.6) 21.8 (14.1) 8.67 (18.1) 
   Drive Safely 45.3 (23.3) 30.3 (29.0) 42.1 (24.4) 24.1 (26.9) 
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Table 4  
Main Effects and Interactions for Mood and Fatigue Measures 
 Time Drug Time x Drug Time x Drug x Sex 
Measures F p ƞp
2
 F p ƞp
2
 F p ƞp
2
 F p ƞp
2
 
POMS subscales:             
  Total Mood 
Disturbance 
0.26 .603 .008 0.01 .906 <.001 0.16 .696 .004 2.33 .136 0.06 
  Tension-Anxiety 1.61 .213 .043 0.19 .670 .005 0.12 .736 .003 0.41 .710 0.004 
  Depression-Dejection 1.82 .186 .048 0.54 .469 .015 6.60 .014 .155 2.65 .315 0.03 
  Anger-Hostility 1.34 .255. .036 1.60 .214 .042 1.73 .197 .046 0.04 .850 0.001 
  Vigour-Activity 3.69 .063 .093 7.07 .012 .164 18.59 p<.001 .340 0.04 .949 <.001 
  Fatigue-Inertia 4.92 .033 .120 11.63 .002 .245 11.88 .001 .248 5.54 .336 0.03 
  Confusion- 
Bewilderment 
2.92 .096 .075 0.003 .958 <.001 1.53 .224 .041 2.42 .222 0.04 
KSS 7.68 .009 .180 0.59 .446 .017 16.67 p<.001 .323 0.87 .356 0.03 
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Subjective Performance and Drug Effects 
 There was a significant main effect of Time for the statement relating to the perceived 
ability to drive safely (Table 5). Participants perceived ability to drive safely was higher at 
baseline than post-ingestion. There was a significant main effect of Drug for the statements 
relating to perceived task ability and perceived ability to drive safely. Participants perceived 
task ability was higher in the modafinil condition compared to placebo. Participants 
perceived ability to drive safely was also higher in the modafinil condition placebo. There 
was a significant Time x Drug interaction for the statements relating to alert level and 
perceived driving impairment. Planned comparisons indicate a significant increase in 
alertness from baseline to post-ingestion after modafinil (p=.013, g=0.49) and a significant 
decrease in alertness from baseline to post ingestion after placebo (p=.007, g=0.62). There 
were significant increases in both modafinil (p=.004, g=0.47) and placebo conditions 
(p<.001, g=0.89) from baseline to post ingestion in perceived driving impairment. The Time 
x Drug x Sex interaction was not significant for any of the VAS statements.  
 For VAS of subjective drug effects at post-ingestion, participants reported 
significantly stronger drug effects in the modafinil condition (M=37.97, SD=30.32) than the 
placebo condition (M=23.03, SD=22.81), t(36)=2.57, p=0.15, g=0.55). The liking of the drug 
effect was stronger in the modafinil condition (M=57.62, SD=21.53) than placebo (M=44.70, 
SD=15.95), t(36)=3.12, p=.004, g=0.67. Participants were more alert in the modafinil 
condition (M=63.51, SD=25.90) than the placebo condition (M=43.84, SD=23.09), 
t(36)=3.85, p<.001, g=0.79. There was no difference between modafinil (M=9.47, SD=15.56) 
and placebo conditions (M=9.08, SD=16.96) in the perceived intoxication level, t(36)=0.12, 
p=.907, g=0.02. The Drug x Sex interaction was not significant for any of the VAS drug 
effects statements.  
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Table 5  
Main Effects and Interaction Results for VAS Subjective Performance Measures 
 
 
 
 
 
 
 Time   Drug   Time x Drug Time x Drug x Sex 
Measures F p ƞp
2
 F p ƞp
2
 F p ƞp
2
 F p ƞp
2
 
Alert 55.87 p<.001 .615 17.81 p<.001 .337 8.20 .007 .190 0.15 .697 0.005 
Task Ability 1.26 .270 .035 6.20 .018 .150 0.63 .432 .018 0.17 .684 0.005 
Impaired Driving 45.07 p<.001 .563 22.25 p<.001 .389 9.04 .005 .205 0.45 .507 0.01 
Drive Safely 24.74 p<.001 .414 11.61 .002 .249 0.63 .434 .018 2.61 .115 0.07 
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Reaction Time 
A repeated measures ANOVA revealed a significant main effect of Cue (Table 6). 
Pairwise comparisons revealed that reaction time was significantly faster following central 
cue trials (M=510, SD=51) than no cue trials (M=529, SD=53.). Reaction time was also 
significantly faster following spatial cue trials (M=461, SD=48.) than central cue trials. The 
reaction time following spatial cue trials was significantly faster than trials following no cue. 
There was a significant main effect of Sex. The reaction time for males (M=475, SD=49) was 
significantly faster than the reaction time for females (M=525, SD=49). 
The Time x Drug interaction was significant. Pairwise comparisons were conducted 
for each drug condition on each time point. Reaction time for the modafinil condition was 
faster at post-ingestion than baseline but this did not reach significance but did produce a 
small effect, (p=.081, g=0.25). The reaction time for the placebo condition did not differ 
between baseline and post-ingestion.  
The Time x Cue interaction was significant. Pairwise comparisons were conducted 
separately for each cue type. Reaction time for spatial cues was significantly faster at post-
ingestion than at baseline (p=.042, g=0.21). There were no significant differences between 
baseline and post-ingestion for central cue (p=.277, g=0.13) or no cue types (p=.784, g=0.03).  
The Time x Drug x Cue interaction was not significant, but hypothesis driven 
pairwise comparisons were conducted for Time for each cue type and drug condition (See 
Figure 2). There was a small significant decrease in reaction time for central cue trials in the 
modafinil condition from baseline to post-ingestion (p=.038, g=0.30) and a small non-
significant increase in reaction time between baseline and post-ingestion for the placebo 
condition (p=.249, g=0.11). For targets following no cue, there was a small non-significant 
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decrease in reaction time between baseline and post-ingestion for the modafinil condition 
(p=.365, g=0.15) and a small increase in reaction time between baseline and post-ingestion 
for the placebo condition (p=.010, g=-0.25). For spatial cue trials, there was a small 
significant decrease in reaction time from baseline to post-ingestion for modafinil (p=.017, 
g=0.31) and a negligible non-significant difference between baseline and post ingestion for 
placebo (p=.648, g=0.04).  
The hypothesised Sex x Cue interaction was not significant. Hypothesis driven 
pairwise comparisons were conducted separately for each cue type. For no cue trials, males 
had a large significantly faster reaction time than females (p=.013, g=0.87). For central cues, 
males had a large significantly faster reaction time when compared to females (p=.010, 
g=0.91). For spatial cues, males had a large significantly faster reaction time than females 
(p=.002, g=1.15). 
 
Figure 2. Reaction Time at Baseline and Post Ingestion for Drug Condition and Cue Type 
(error bars represent 95%CI’s). 
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Table 6 
Main Effects and Interaction Results for Reaction Time Analyses 
Factor F df p ƞp
2
 
Time 0.78 1, 34 .384 .022 
Drug 0.46 1, 34 .502 .013 
Cue 343.59 1.6 53.8 <.001 .910 
Sex 8.74 1, 34 .006 .204 
Time x Sex 0.08 1, 34 .774 .002 
Drug x Sex 1.80 1, 34 .189 .050 
Cue x Sex 1.64 1.6, 53.8 .207 .046 
Time x Drug 5.94 1, 34 .020 .149 
Time x Cue 10.04 1.9, 64.3 <.001 .228 
Drug x Cue 1.54 1.9, 64.6 .221 .043 
Time x Cue x Sex 1.37 1.9, 64.3 .262 .039 
Time x Drug x Sex 0.009 1, 34 .924 <.001 
Drug x Cue x Sex 0.60 1.9, 64.6 .554 .017 
Time x Drug x Cue 1.67 1.7, 56.5 .202 .047 
Time x Drug x Cue x Sex 0.23 1.7, 56.5 .754 .007 
 
Accuracy 
A repeated measures ANOVA revealed a significant main effect of Time (Table 7). Accuracy 
was significantly higher at baseline (M=95.71, SD=3.30) than post-ingestion (M=93.94, 
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SD=4.05). There was also a significant main effect of Drug. Accuracy was significantly 
higher after modafinil ingestion (M=95.39, SD=3.37) than after placebo (M=94.27, SD=3.80). 
The main effect of Cue was significant. Accuracy was significantly higher following spatial 
cues (M=95.74, SD=3.34) than following both no cue (M=94.85, SD=3.56) and central cue 
trials (M=93.90, SD=3.62). Accuracy following no cue was significantly higher than 
following central cues. There were no significant effects related to Sex. 
 
Table 7 
Main Effects and Interactions Results for Accuracy Analyses 
Factor F df p ƞp
2
 
Time 10.21 1,34 .003 .231 
Drug 5.57 1, 34 .024 .141 
Cue 14.32 1.9, 66.2 <.001 .298 
Sex 0.90 1, 34 .351 .026 
Time x Sex 0.61 1, 34 .442 .017 
Drug x Sex 0.31 1, 34 .582 .009 
Cue x Sex 1.26 1.9, 66.2 .290 .036 
Time x Drug 2.21 1, 34 .146 .061 
Time x Cue 2.48 1.7, 58.4 .100 .068 
Drug x Cue 0.61 1.7, 56.5 .516 .018 
Time x Cue x Sex 1.12 1.7, 58.4 .332 .032 
Time x Drug x Sex 0.66 1, 34 .424 .019 
Drug x Cue x Sex 0.56 1.7, 56.5 .543 .016 
31 
 
 
 
Time x Drug x Cue 2.19 1.9, 66.1 .122 .060 
Time x Drug x Cue x Sex 0.19 1.9, 66.1 .823 .006 
 
N1 Amplitude 
A repeated measures ANOVA revealed a significant main effect of Cue for N1 
amplitude at post-ingestion (Table 8, Figures 3 & 4). Pairwise comparisons revealed that N1 
amplitude was significantly greater following central cue trials (M=-2.06, SD=2.93) than 
following no cue trials (M=-1.35, SD=2.42). N1 amplitude was also significantly greater 
following spatial cue trials (M=-4.53, SD=2.68) than following both central cue and no cue 
trials.  
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Figure 3. Grand Mean Waveforms for Each Cue Type by Drug Condition for Females at 
Occipital Site OZ 
 
 
 
Figure 4. Grand Mean Waveforms for Each Cue Type by Drug Condition for Males at 
Occipital Site OZ 
The main effects of Drug and Sex were both non-significant, but there was a 
significant Drug x Sex interaction. Pairwise comparisons were conducted comparing 
modafinil and placebo conditions for each sex. For females, the effect of drug was not 
significant (p=.206, g=0.15). For males, the effect of drug was significant, with N1 amplitude 
significantly greater in the modafinil condition than the placebo condition (p=.039, g=0.24). 
 The hypothesised Drug x Cue interaction was not significant. Planned hypothesis 
driven comparisons were conducted on drug condition separately for each cue type. There 
was no significant difference between modafinil and placebo conditions for any of the cue 
type, no cue (p=.263, g=0.08), central cue (p=.985, g<.001) or spatial cue (p=.683, g=0.06). 
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Table 8  
Main Effects and Interactions Results for N1 Amplitude at post-ingestion 
Factor F df p ƞp
2
 
Drug 2.20 1, 34 .147 .061 
Cue 54.35 1.5, 50.4 <.001 .615 
Sex 1.60 1, 34 .215 .045 
Drug x Sex 5.64 1, 34 .023 .142 
Cue x Sex 2.15 1.5, 50.4 .139 .060 
Drug x Cue 0.41 1.6, 54.3 .619 .012 
Drug x Cue x Sex 2.25 1.6, 54.3 .126 .062 
 
Discussion 
 The aim of the present study was to investigate the effect of 200mg of modafinil on 
attentional alerting and orienting networks in a healthy non-sleep deprived sample using an 
attentional network task. A further aim was to examine both male and female participants to 
investigate any associated sex differences in attention and modafinil effects. As hypothesised 
and consistent with Neuhaus et al. (2010), reaction time decreased as cues became more 
informative. Reaction time was significantly faster for central cues than no cue trials, and 
significantly faster for spatial cues when compared to both central and no cue trials. This 
pattern was also found for N1 amplitude, supporting the hypothesis and the findings of 
Neuhaus et al. (2010), that N1 amplitude would increase as cues became more informative. 
Consistent with the hypothesis, there was a small enhancement of the alerting network, 
demonstrated by a small decrease in reaction time from baseline to post-ingestion for 
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modafinil but not placebo. There also appeared to be a small enhancement of the orienting 
network which was not hypothesised, as reaction time for spatial cues was faster at post-
ingestion than at baseline, but this effect was not greater than the alerting effect. Reaction 
time for males was faster overall for males and males also showed faster reaction time for 
each cue type, which was not hypothesised. Males showed a greater N1 amplitude after 
modafinil than placebo which was not present for female participants, indicating that 
modafinil may effect the sexes differently.  
Mood, Fatigue and Alertness 
 There was a significant increase in fatigue (KSS) and fatigue-inertia (POMS) from 
baseline to post-ingestion for the placebo condition but not modafinil. Vigour-activity 
significantly decreased from baseline to post-ingestion in the placebo condition. Alertness 
(VAS) was significantly higher from baseline to post-ingestion for modafinil and lower for 
placebo. Perceived driving ability and perceived task ability were both higher in the 
modafinil condition than the placebo condition. These results suggest that overall; modafinil 
decreases fatigue and increases overall alertness, which is supported by other studies 
(Baranski et al. 2004; Ikeda et al. 2017). 
 The depression-dejection subscale decreased significantly from baseline to post-
ingestion in the modafinil condition but not placebo. This is consistent with modafinil 
inhibiting the reuptake of dopamine, creating feelings of euphoria, and suggests why 
modafinil is becoming more commonly used in treatment of depression (Minzenberg & 
Carter, 2008).  
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Attentional Network Task  
  There was a significant decrease in reaction time between no cue and central cue trials 
as hypothesised. There was also a significant decrease in reaction time between central cue 
and spatial cue trials, which was also hypothesised. These findings are consistent with 
Neuhaus et al. (2010), who found that reaction time decreases as the cue becomes more 
informative. Faster reaction time for central cues relative to no cue indicates activation of the 
alerting network, while faster reaction time for spatial cues relative to central cues indicates 
activation of the orienting network. This indicates activation of both alerting and orienting 
networks by their respective cue types in the attentional network task used in this study.  
  N1 amplitude was significantly greater (more negative) for central cues than no cue. 
N1 amplitude was also significantly greater for spatial cues than central cues. These results 
are consistent with the hypotheses, and also with Neuhaus (2010)’s findings. Neuhaus et al. 
(2010) found that N1 amplitude becomes greater as cues are more informative, indicating 
activation of both alerting (central cue) and orienting networks (spatial cue). 
Alerting Network 
 The Time x Drug x Cue interaction for reaction time was not significant, however 
pairwise comparisons revealed some potential enhancement of the alerting network. The 
decrease in reaction time between baseline and post-ingestion was small and significant for 
the modafinil condition, but was not significant for the placebo condition. This suggests some 
alerting network enhancement after modafinil ingestion. This is consistent with the 
hypotheses that modafinil would enhance the alerting network and consistent with some 
previous research. Studies that have used a more complex task have found consistent effects 
of modafinil on the alerting network (Baranski et al. 2004; Cope et al. 2017; Ikeda et al. 
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2017; Theunissen et al. 2009). Ikeda et al. (2017) found that in an attentional network task, 
participants had a faster reaction time after modafinil compared to placebo. Using a 
Mackworth clock test, faster reaction time was also found after modafinil ingestion when 
compared to placebo (Theunissen et al. (2009). Modafinil also improved accuracy on the 
attentional network task in this study, consistent with Cope et al. (2017) and Baranski et al. 
(2004) who found that modafinil ingestion resulted in increased ability to detect targets on a 
5-choice continuous performance task and a detection of repeated numbers task respectively.  
 These results are not consistent with some previous research that has found no effect 
of modafinil on the alerting network. These tasks are simple in nature and have been 
suggested to not be complex enough to detect differences between modafinil and placebo 
conditions in a healthy population due to ceiling effects (Battleday & Brem, 2015). Turner et 
al. (2003) and Randall et al. (2005) used a RVIP task to analyse sustained attention and both 
found that modafinil did not improve performance on the task. A reaction time task also 
failed to find any enhancing effects of modafinil on the alerting network (Liepert et al. 
(2004). The results of the current study are not consistent with these findings, with some 
enhancement of the alerting network found.  
 The Drug x Cue interaction and associated planned comparisons, specifically for 
central cues were not significant. This suggests no enhancement of the alerting network for 
this dependent variable following modafinil ingestion. The result is inconsistent with the 
reaction time results, which showed some alerting network enhancement on further 
investigation of the results. As this is the first study to use N1 amplitude as a dependent 
variable, there are no comparisons studies to help explain why these results have occurred.   
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Orienting Network 
 While the Time x Drug x Cue interaction was not significant, pairwise comparisons 
revealed that there was a small decrease in reaction time from baseline to post-ingestion for 
modafinil that was not present for placebo. It was hypothesised there would be no difference 
between modafinil and placebo conditions following spatial cues, consistent with Ikeda et al. 
(2017). The effect found was small and was similar in size to the effect found for the alerting 
network. As spatial cues also include an alerting component (warns participants to oncoming 
target as well as location), it is possible that the effect found is related to enhancement of the 
alerting network rather than specific enhancement of the orienting network (Petersen & 
Posner, 2012).  
 Consistent with the hypothesis, there was no difference between modafinil and 
placebo conditions in N1 amplitude for spatial cues. This result suggests that there was no 
enhancement of the orienting network after modafinil ingestion, which is consistent with 
Ikeda et al. (2017). As little research has been conducted into the effect of modafinil on the 
orienting network, more is needed to determine possible effects.  
Sex Differences in Attentional Networks 
 It was expected that female participants would have a faster reaction time to spatial 
cues than male participants. However, the results showed that male participants had a faster 
reaction time overall and also for each specific cue type. Merritt et al. (2007) found that 
males had a faster overall reaction time on a spatial cuing task, which is consistent with the 
findings of this study. However, it was not expected that males would respond to spatial cues 
faster than female participants, as Merritt et al. (2007) also found that females showed a 
benefit to valid cues (present in the ANT) and males showed a benefit to invalid cues (not 
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present in the ANT). Liu et al. (2013) found that females responded to spatial cues faster in 
an attentional network task than males, and found no difference between the sexes for central 
and no cue types. This is the first study to find a difference between males and females on 
central and no cue types (Liu et al. 2013; Xiao et al. 2016). There were more male 
participants recruited than females, which could indicate why this effect occurred due to the 
lack of power in the female sample.  
 There was no difference between females and males in N1 amplitude for any cue 
type. This is inconsistent with findings by Neuhaus et al. (2009) who found females had 
greater N1 amplitude after spatial cues than males. Males showed greater N1 amplitude 
following modafinil compared to placebo than females. This is the first study to investigate 
the differential effects of modafinil on males and females. Therefore, these results could 
indicate that modafinil could have a greater impact on males than females, but more research 
would be required to confirm this, as in the current study the female sample lacked power to 
detect any true differences.  
Implications 
 This is the first study to investigate the effects of modafinil on ERP measures of 
attention (N1 component) and also include both male and female participants. The results 
suggest some small alerting network enhancement and potentially orienting network 
enhancement. While small in nature, these effects suggest that modafinil can be effective to 
enhance some aspects of attention (mainly alerting network). As modafinil is commonly used 
by shift workers, it is likely to result in some improvement in attention when compared to no 
drug (Minzenburg & Carter, 2008). Males showed greater N1 amplitude after modafinil than 
females, suggesting some sex differences in the effects of modafinil. However, more research 
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is needed to confirm this finding. This study only investigated the effects of modafinil on 
attention based on a single dose of modafinil. Future studies should investigate the effect of 
repeated doses of modafinil to determine if the enhancing effects are likely to be effective for 
long-term use. Modafinil could also be investigated in comparison to other possible attention 
enhancers such as caffeine to determine if modafinil is the best choice as a cognitive 
enhancer (Brunyé, Mahoney, Lieberman, & Taylor, 2010).    
Limitations 
 The sample size for the current study was inconsistent across the sexes, with more 
male participants recruited than female participants. This is an issue for the power of the 
statistical analyses involving sex as a factor. This is because the female sample was small, 
and therefore lacked sufficient power to detect any differences (Button et al. 2013). For future 
studies, it would be ideal to have equal samples of each sex to more accurately determine the 
sex differences in attention and if modafinil has differential effects.  
 The findings into the effects of modafinil on the attentional networks has been mixed. 
A possible reason is because the tasks used are not complex enough to detect the effects of 
modafinil in a healthy non-sleep deprived sample with an overall high IQ. The sample for the 
present study primarily included university students (79.9%), with a mean WTAR score 
higher than average. The general high IQ of this sample could indicate that the task was not 
complex enough to detect the effects of modafinil in this sample, as many hypothesised 
interactions were non-significant. Future studies should attempt to use a more diverse sample 
or incorporate IQ into the analysis (Randall et al. 2005) to more accurately determine the 
effects of modafinil on attention.  
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 Baseline ERP measure were not collected in the present study for comparison to the 
post-ingestion data. The time constraints for the present study meant that it was not feasible 
to collect ERP data at both baseline and post-ingestion due to the time consuming nature of 
the EEG set-up. Future studies should incorporate baseline ERP measures for comparison to 
post-ingestion if time is not an issue.  
 Another potential limitation is that peak plasma levels were only estimated based on 
other modafinil research rather than using blood samples from each participant. This means 
that the time of testing may not have been ideal for each participant due to individual 
differences in rates of absorption. While invasive due to the need to collect blood samples, 
future studies should base time of testing on each individual participant rather than estimating 
based on other research.  
 As participants were more likely to think that they had taken modafinil in the 
modafinil condition, it is possible that some expectancy effects occurred. Participant’s 
expectations about how they should be reacting after the drug ingestion could have affected 
their overall results to support those expectancies. A double-blind procedure was used to try 
and eliminate these effects. Furthmore. as participants were generally only on average around 
50% sure they had taken modafinil, these effects would have likely been minimal.  
Conclusion 
 The aim of the current study was to investigate the effects of 200mg of modafinil on 
behavioural (reaction time) and neural (N1 amplitude) measures of attentional alerting and 
orienting networks in a healthy non-sleep deprived sample.  Reaction time and N1 amplitude 
decreased and increased respectively as cues became more informative, indicating activation 
of the respective networks (Neuhaus et al., 2010). Pairwise comparisons indicate a small 
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significant enhancement of the alerting network, demonstrated by a decrease in reaction time 
from baseline to post-ingestion for modafinil but not placebo. This was consistent with the 
hypotheses relating to the alerting network. However, N1 amplitude was not greater after 
modafinil ingestion as expected, and conflicting with the reaction time results. Future 
research is needed to investigate these effects further.  
 There was a small significant decrease in reaction time from baseline to post-ingestion 
for spatial cues. This effect similar to the alerting effect, and was likely due to the alerting 
enhancement rather than specific enhancement of the orienting network. There was no 
increase in N1 amplitude after modafinil, as expected.  
 The hypotheses relating to sex differences were all not supported, with males 
revealing faster reaction time overall and for each specific cue type. This is the first study to 
suggest a difference between males and females for both central cues (alerting) and no cue 
types. There was no difference between males and females for N1 amplitude, which was not 
expected. A reason for these findings could relate to the sample size, with more male 
participants recruited than female participants. Males showed greater N1 amplitude after 
modafinil ingestion when compared to placebo than females did. No other study has looked 
at sex differences in the effects of modafinil and this needs to be further investigated. 
 These findings are consistent with previous findings into alerting enhancement after 
modafinil. However, the orienting network has not been substantially researched and more 
research is required to determine if modafinil does have some enhancing effects on this 
network. While executive control was not the focus of the current study, future study should 
also investigate the effects of modafinil on this network, particularly ERP measures. Future 
studies should also aim to investigate the effects of modafinil on both sexes, with equal 
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sample sizes. Other limitations should also attempt to be addressed, including recoding 
baseline ERP data and accurately determining peak plasma levels of modafinil in 
participants.  
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Appendix A: Ethics Approval 
 
From: human.ethics@utas.edu.au [mailto:human.ethics@utas.edu.au] 
Sent: Thursday, 27 July 2017 11:03 AM 
To: Raimondo Bruno <raimondo.bruno@utas.edu.au> 
Cc: chris.wake@ths.tas.gov.au; Allison Matthews <allison.matthews@utas.edu.au>; Jessica 
Hartley <jessica.hartley@utas.edu.au>; Research Ethics <Human.Ethics@utas.edu.au> 
Subject: Notification of Amendment Approval: H0011386 The effect of modafinil on 
simulated driving performance 
 
Dear AssocProf Bruno, 
Ethics Ref: H0011386 
Title: The effect of modafinil on simulated driving performance 
 
This email is to confirm that the following amendment was approved by the Chair of the 
Tasmania Health and Medical Human Research Ethics Committee on 27/7/2017: 
Amendment to assist with recruitment and to allow investigation of sex differences in 
cognitive processing, the recruitment criteria will be broadened to include females 
 
Miscellaneous Modafinil_poster_revised_2017 Information Sheet MODAFINIL info and 
consent forms_revised_2017 Miscellaneous MODAFINIL_questionnaires_revised2017 
Application Form revised NEAF - Modafinil_NEAF_amendment_210717 
 
All committees operating under the Human Research Ethics Committee (Tasmania) Network 
are registered and required to comply with the National Statement on Ethical Conduct in 
Human Research (NHMRC 2007). 
This email constitutes official approval. If your circumstances require a formal letter of 
amendment approval, please let us know. 
 
Should you have any queries please do not hesitate to contact me. 
Kind regards 
Christy Nixon 
 
Christy Nixon 
Funding Support 
Office of Research Services 
University of Tasmania 
Private Bag 01 
Hobart TAS 7001 
Phone: (03) 6226 7592 
Fax: (03) 6226 2765 
Email: Christy.Nixon@utas.edu.au 
Web: http://www.utas.edu.au/research-admin 
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Appendix B: Information Sheet 
INFORMATION SHEET 
 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
 
Chief Investigators: Dr Raimondo Bruno & Dr Allison Matthews 
Researchers: Tanya Wilson and Hannah Shaw *  
*This research is being conducted as part of an Honours degree in the School of 
Psychology, UTAS. 
 
We would like to invite you to participate in a study aiming to better understand the 
way that the prescription drug Modafinil effects cognitive processes such as attention 
and associated brain activity. The use of this drug is increasing Australia wide, and we 
are interested in better understanding its effects. There have been a number of studies 
which have shown some effects of stimulant drugs on cognitive processes but very few 
studies have examined Modafinil. Getting a better understanding about Modafinil is 
particularly important, not just to understand how the drug affects cognition, but also to 
be able to provide information for doctors to give to potential users of the drug. 
 
Why have I been invited to participate in this research? 
You are invited to take part in the study if you are aged 18-30 years old. In order for the 
results of the study to be clear, all participants need to speak English fluently, and have 
had no previous neurological or mental health problems. In addition participants must 
NOT use illicit drugs, smoke cigarettes daily, consume alcohol at harmful levels. All 
females will need to need to indicate that there is no chance that they might be 
pregnant, and are recommended to refrain from sexual intercourse for 48 hours after 
each experimental session to reduce any potential of harm if a pregnancy was to arise. 
In addition, females currently on hormonal contraception (e.g., the contraceptive pill 
and implanon) will need to be willing to abstain from sex or use barrier-based 
contraception (e.g., condoms) during and for four weeks after the study. This is based 
on evidence that Modafinil may decrease the effectiveness of hormone-based 
contraceptives. This advice does not apply to the following forms of contraception 
which should remain effective: depo-provera injections, mirena or copper IUDs.  
 
What will my participation involve? 
Participating in this study is unlikely to cause any discomfort or distress. Firstly, if you 
are interested in taking part in the study, you will be invited to complete a series of 
confidential screening questionnaires. These will enquire about what your mood has 
been like recently. This will include a psychological distress scale, schizotypal 
personality questionnaire, a psychosis screener and some questions regarding your 
alcohol and drug use. All data collected will be kept in the strictest confidence, and the 
way we maintain this is described below. This screening process is simply to ensure 
that participants in the study are not taking medications or experiencing other issues 
that may cause a negative response to Modafinil.   
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During the study, we will ask for some basic information about yourself (such as age, 
sex, years of schooling). During each testing session, you will be fitted with an electrode 
cap for measuring your brain activity. You will be asked to complete some computer-
based tasks which relate to cognitive processes such as attention. In these tasks you will 
respond with a button press when particular stimuli appear on the screen. Previous 
studies using the same dose of Modafinil have found side effects for some participants, 
including dry mouth, mild headaches and mild nausea. There will be two testing 
sessions which will occur at the University of Tasmania, and will take around four hours 
each. You will be reimbursed $80 for your time and out-of-pocket expenses. 
 
Before taking part in the study you must organise for a reliable friend or family member 
to collect you from the lab at the end of the testing session, in case you are still 
experiencing any effects following the possible administration of Modafinil. The 
researcher will check that this has been organised before the testing session begins. 
When the nominated person collects you, they will be given a copy of the medication 
information sheet about Modafinil, and the main points will be verbally explained. 
Namely, it will be explained that they should ensure you do not drive a vehicle or 
operate machinery for the rest of the day, and do not consume alcohol. In the unlikely 
event that you do experience unpleasant side effects while completing the testing, the 
researchers are trained in first aid, and the chief investigators will be available on site to 
provide further assistance if required. Additionally, the researcher will explain that in 
the unlikely event of you experiencing an adverse reaction once you have left the 
premises, you should contact your doctor or be taken to hospital immediately. 
 
There are no specific risks associated with the measurement of brain activity. However, 
if you have sensitive skin there is a small possibility of a slight skin reaction from 
electrode preparation materials. If you believe there is a chance that your skin may 
react you are advised to reconsider participation. 
 
How private is the information that I give? 
It is important for you to know that all data collected will be kept in the strictest 
confidence. All data will be identified by a coding system and no names or contact 
numbers will appear on any records. In this way, your identity is protected, and there 
will be no risk of legal or social problems arising from your participating in the study. 
All information gathered in the study will be reported as grouped data, and because no 
personal information is recorded, no individual participants will be identifiable in the 
research output. Data from the study will be stored securely for five years in locked 
cabinets in the School of Psychology, as is legally required, and then destroyed by 
shredding. 
 
Can I withdraw from the research if I wish? 
Participation in this study is entirely voluntary. You may, at any time, decline to answer 
any question you so wish, or withdraw from the study without effect or explanation.You 
will be given a copy of this information sheet to keep. Please retain this information 
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sheet in case you decide at a later data that you would like to retract your data from the 
study.  
 
Who do I need to contact if I have any questions about the research? 
If you would like more information about the research, please contact Dr Allison 
Matthews on 62267236 (or email Allison.Matthews@utas.edu.au) or Dr Raimondo 
Bruno 6226 2190 (Raimondo.Bruno@utas.edu.au). If you would like to find out about 
the results of the study, these will be available from Dr Matthews after November 2016 
or at www.utas.edu.au/psychol.  
 
Has this research been approved by an ethics committee? 
This project has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. If you have any concerns of an ethical nature, or complaints about the 
manner in which the study is conducted, you may contact the Executive Officer of the Human 
Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
human.ethics@utas.edu.au. Please quote the ethics reference number H11386. 
Who can I contact if I have any concerns? 
If you have any personal concerns related to the study, you may choose to discuss these 
concerns confidentially with a counsellor at the University Psychology Clinic free of 
charge. Confidential appointments may be made on (03) 6226 2805. 
Thank you for your interest in the study and for taking the time to read this information 
sheet. We hope you will be interested in participating in this study. 
 
Raimondo Bruno & Allison Matthews  Tanya Wilson/Hannah Shaw 
Chief Investigators                      Student Researchers   
(03) 6226 2190 or (03) 6226 7236  
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Appendix C: Consent Form 
CONSENT FORM 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
  
1. I have read and understood the 'Information Sheet' for this study. 
2.  I have read and understood the ‘Consumer Medicine Information’ regarding 
modafinil. 
3. The nature and possible effects of the study have been explained to me. I 
understand that I should refrain from sex for 48 hours after each experimental 
session to reduce potential harm if an unplanned pregnancy were to arise. I may 
also need to abstain from sex or use barrier-based contraception (e.g., condoms) 
during and for four weeks after the study to ensure effectiveness of certain forms 
of hormonal contraception (e.g., the contraceptive pill and implanon). 
4. I understand that the study involves: 
 Attending two testing sessions of approximately four hours duration 
 Completing a series of cognitive tasks while my brain activity is measured 
5. I understand that all research data will be securely stored on the University of 
Tasmania premises for five years, and will then be destroyed. 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered from me for the study may be published 
provided that I cannot be identified as a participant. 
8. I understand that the researchers will maintain my identity confidential and that 
any information I supply to the researcher(s) will be used only for the purposes of 
the research. 
9. I agree to participate in this investigation and understand that I may withdraw at any 
time without any effect, and if I so wish, may request that any data I have supplied to 
date be withdrawn from the research. 
10. This project has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. If you have any concerns of an ethical nature, or complaints about 
the manner in which the study is conducted, you may contact the Executive Officer of 
the Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
human.ethics@utas.edu.au. Please quote the ethics reference number H11386. 
  
Name of Participant: 
Signature: Date: 
 
Statement by Investigator  
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 I have explained the project & the implications of participation in it to this 
volunteer (including the potential for modafinil to reduce the effectiveness 
of hormonal contraception) and I believe that the consent is informed and 
that he/she understands the implications of participation  
 
Name of Investigator 
Signature: Date: 
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Appendix D: Modafinil Consumer Medical Information 
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Appendix E: Screening Questionnaire 
 
 
Screening questionnaire 
 
 
How old are you? 
 
___________________ 
Participants must be males between 18 and 30. 
Do you smoke? 
If yes, participant is not eligible for the study. 
Yes   No  
Is English your first language? Yes   No  
For females: Are you currently pregnant or is there any chance that 
you could be pregnant or are you currently trying to conceive? 
 (if Yes, exclude from the research) 
Yes   No  
For females: Are you currently using the following forms of 
hormonal contraception (contraceptive pill or implanon)? 
Specify here__________________ 
Note: the following advice does not apply to depo-provera injections, 
mirena or copper IUDs 
Yes   No  
If yes, would you be happy to abstain from sex or use barrier-based 
contraception for 4 weeks from the conclusion of the study? 
Yes   No  
    No  
Have you ever used any of the following:  
Heroin Yes   No  
Methamphetamine (speed powder, base, ice) Yes   No  
Ecstasy Yes   No  
Cocaine Yes   No  
Hallucinogens (e.g. LSD, acid, magic mushrooms) Yes   No  
Inhalants (e.g. amyl nitrate, rush, glue, laughing gas, petrol, 
paint) 
Yes   No  
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Other illicit drug Yes   No  
Have you ever used pharmaceutical medications without 
them being prescribed to you, e.g. morphine, methadone, 
oxycodone, pharmaceutical stimulants, antipsychotics, 
antidepressants? 
Yes   No  
Q1. How often do you have a drink containing alcohol? 
0  Never 
1 Monthly or 
less 
2 2-4 times a 
month 
3 2-3 times 
a week 
4 4 or more 
times a week 
Q2. How many drinks containing alcohol do you have on a typical day when you are 
 drinking? 
0 1 or 2 1 3 or 4 2 5 or 6 3 7 to 9 4 10 or more 
Q3. How often do you have six or more drinks on one occasion? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
 
Do you have a history of any of the following:  
Major Anxiety/Depression Yes   No  
Mania Yes   No  
Psychosis/ any other psychological illness Yes   No  
Attention deficit/hyperactivity disorder Yes   No  
Alcohol or substance use problems Yes   No  
Hypertension Yes   No  
Cardiac problems (inc. chest pain/angina)  Yes   No  
Liver impairment Yes   No  
Kidney impairment  Yes   No  
Epilepsy  Yes   No  
Chronic Pain  Yes   No  
Asthma Yes   No  
Skin complaints Yes   No  
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Severe head injury Yes   No  
Fits/convulsions Yes   No  
Loss of consciousness >2 minutes Yes   No  
Multiple concussions (or any concussion in last 6 weeks) Yes   No  
Regular giddiness Yes   No  
Sleep disorders or major sleeping difficulties Yes   No  
Dyslexia Yes   No  
Visual impairment Yes   No  
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Are you currently taking any medications: (including over-
the-counter medications) 
Yes   No  
For safety, please verify specifically:      
Methylphenidate (a drug used for ADHD & narcolepsy) Yes   No  
Triazolam (or any benzodiazepine used, for example, in the 
treatment of insomnia or anxiety) 
Yes   No  
Psychiatric meds for depression (inc. Herbal- hypericum 
St.Johns Wort), or schizophrenia  
Yes   No  
Phenytoin or other anticonvulsants (any drugs used for 
epilepsy) 
Yes   No  
Warfarin (anticoagulant, blood thinner) Yes   No  
Codeine, fentanyl (or any drugs used for chronic pain) Yes   No  
Hormone supplements (testosterone) Yes   No  
Daily paracetamol or ibuprophen Yes   No  
Medications to treat fungal infections Yes   No  
Medications to help you sleep Yes   No  
Any other medicines, including any available without a 
prescription from a pharmacy, supermarket or health food 
store 
Yes   No  
Any medications over the past week (other than PRN 
paracetamol) 
Yes   No  
     Caffeine use 
Q1. How often do you have a drink containing caffiene? 
0  Never 1 Monthly or less 2 2-4 times a month 
3 2-3 times a 
week 
4 4 or more times a 
week 
Q2. How many drinks containing caffiene do you have on a typical day when you have caffiene? 
0 1 or 2 1 3 or 4 2 5 or 6 3 7 to 9 4 10 or more 
Q3. How often do you have six or more drinks on one occasion? 
 
Do you have notice any adverse side effects when you drink caffeine?  Yes  / No 
Weight____________ kg 
Height______________ cm 
Estimated BMI: ____________ 
Are you left or right handed?   
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1. In the past 12 months, have you felt that your thoughts were being 
directly interfered with or controlled by another person? 
Yes      
No    
1a. Did it come about in a way that any people would find hard to 
believe, for instance, through telepathy? 
Yes      
No    
2. In the past 12 months, have you had a feeling that people were too 
interested in you? 
Yes      
No    
2a. In the past 12 months, have you had a feeling that things were 
arranged so as to have a special meaning for you, or even that harm 
might come to you? 
Yes      
No    
3. Do you have any special powers that most people lack? Yes      
No    
3a. Do you belong to a group of people who also have these special 
powers? 
Yes      
No    
4. Has a doctor ever told you that you may have schizophrenia?  Yes      
No    
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Appendix F: Experimental Questionnaire 
Experimental session questionnaire 
Date ____/____/____       Participant ID 
_____________ 
 
1. Check that participant has abstained from alcohol for 24 hours and illicit drug use since 
completing the screening questionnaire 
2. Weight ___________ kg 
Height____________ cm 
BMI _____________ 
 
3.  Have you consumed any medications in the past week (or any prescribed medications since 
completing the screening questionnaire)? 
If yes, please detail:  
 
3.
 
How 
many 
cups of 
coffee 
(or any 
other 
caffeinated drinks/products) have you consumed today? _____  
If > 0. How many hours since your last caffeinated drink ______ hours 
4. Have you had any tobacco or nicotine products today? Yes / No  
If yes, how many cigarettes (or nicotine products) have you had today? ____ 
If yes, How many hours since your last cigarette (nicotine product) ______ hours 
5.  What have you had to eat today? How long since you last ate something? _________ mins 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
6. Approximately how many hours sleep did you have last night? ____ 
 
Medication Number of 
occasions 
Time since last used Estimated dose 
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These questions are related to your use of alcohol. Remember, any information 
you provide is completely confidential. 
Please circle the most appropriate response 
Q1. How often do you have a drink containing alcohol? 
0  Never 
1 Monthly or 
less 
2 2-4 times a 
month 
3 2-3 times 
a week 
4 4 or more 
times a week 
Q2. How many drinks containing alcohol do you have on a typical day when you are 
 drinking? 
0 1 or 2 1 3 or 4 2 5 or 6 3 7 to 9 4 10 or more 
Q3. How often do you have six or more drinks on one occasion? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
Q4. How often during the last year have you found that you were not able to stop drinking 
once you had started? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
Q5. How often during the last year have you failed to do what was normally expected from 
you because of drinking? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
Q6. How often during the last year have you needed a first drink in the morning to get 
 yourself going, after a heavy drinking session? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
Q7. How often during the last year have you had a feeling of guilt or remorse after drinking? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
Q8. How often during the last year have you been unable to remember what happened the 
night before because you had been drinking? 
0 Never 
1 Less than 
monthly 
2 Monthly 3 Weekly 
4 Daily or 
almost daily 
 
Q9. Have you or someone else been injured as a result of your drinking? 
0 No 2 Yes, but not in last year 4 Yes, during the last year 
Q10. Has a relative or friend or doctor or other health worker been concerned about your 
drinking or suggested you cut down? 
0 No 2 Yes , but not in last year 4 Yes, during the last year 
 
Total =              (>16) 
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Well-Being Scale 
 
These questions are related to how you have been feeling over the last 4 
weeks. Remember, any information you provide is completely confidential. 
Please circle the most appropriate response. 
 
In the last 4 weeks, about how often –  
 
1. Did you feel tired ou t for no good 
reason? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
  
2. Did you feel nervous? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5                
Note: If response 1 chosen, go to Q4 
 
3. Did you feel so nervous that nothing 
could calm you down? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
 
4. Did you feel hopeless? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
 
5. Did you feel restless or fidgety? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
Note: If response 1 chosen, go to Q7 
 
6. Did you feel so restless that you 
could not sit still?                         
     None of the time  1  
     A little of the time 2 
     Some of the time 3  
     Most of the time            4  
     All of the time            5  
 
 
    7. Did you feel depressed? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
 
8. Did you feel that everything was 
an effort? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5 
  
9. Did you feel so sad that nothing 
could cheer you up? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
 
10. Did you feel worthless? 
None of the time  1 
A little of the time 2 
Some of the time 3  
Most of the time 4  
All of the time 5  
Total=              (>30)
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Please answer each item by checking Y (Yes) or N (No). Answer all items even if 
unsure of your answer. When you have finished, check over each one to make sure 
you have answered them. 
1. People sometimes find me aloof and distant 
 
Yes        No   
2.  Have you ever had the sense that some person or force is around you, even 
though you cannot see anyone? 
Yes        No   
3. People sometimes comment on my unusual mannerisms and habits 
 
Yes        No   
4. Are you sometimes sure that other people can tell what you are thinking? 
 
Yes        No   
5. Have you ever noticed a common event or object that seemed to be a 
special sign for you? 
Yes        No   
6. Some people think that I am a very bizarre person 
 
Yes        No   
7. I feel I have to be on my guard with friends 
 
Yes        No   
8.  Some people find me a bit vague and elusive during a conversation 
 
Yes        No   
9. Do you often pick up hidden threats or put downs from what people say or 
do? 
 
Yes        No   
10. When shopping do you get the feeling that other people are taking notice 
of you? 
 
Yes        No   
11. I feel very uncomfortable in social situations involving unfamiliar people 
 
Yes        No   
12.  Have you had experiences with astrology, seeing the future, UFos, ESP, or 
a sixth sense? 
Yes        No   
13. I sometimes use words in unusual ways 
 
Yes        No   
14. Have you found that it is best not to let other people know too much about 
you? 
 
Yes        No   
15. I tend to keep in the background on social occasions 
 
Yes        No   
16.  Do you ever suddenly feel distracted by distant sounds that you are not 
normally aware of? 
Yes        No   
17. Do you often have to keep an eye out to stop people from taking 
advantage of you? 
 
Yes        No   
18.  Do you feel that you are unable to get ‘close’ to people? 
 
Yes        No   
19. I am an odd, unusual person 
 
Yes        No   
20.  I find it hard to communicate clearly what I want to say to people 
 
Yes        No   
21. I feel very uneasy talking to people I do not know well Yes        No   
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22. I tend to keep my feeling  to myself 
 
Yes        No   
Total=               (≥17) 
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Weschler Test of Adult Reading 
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Profile of Mood States-Short Form 
 
Participant Code:              Test Point: 
pre 
 
Below is a list of words that describe feelings people have. Please read each one carefully. 
Then circle ONE answer to the right, which best describes how you are feeling AT THE 
MOMENT. 
 
The numbers refer to these phrases: 
0=not at all 
1=a little 
2=moderately 
3=quite a bit 
4= extremely 
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Participant Code:              Test Point: 
pre 
 
Karolinska Sleepiness Scale 
 
Please circle on the following scale of 1 to 9 how you feel AT THE PRESENT 
MOMENT: 
 
1. Extremely alert 
2. Very alert 
3. Alert  
4. Rather alert 
5. Neither alert nor sleepy 
6. Some signs of sleepiness 
7. Sleepy, but no effort to keep awake 
8. Sleepy, some effort to keep awake 
9. Very sleepy, great effort to keep awake, fighting sleep 
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Visual Analogue Scales of Subjective Performance 
 
Participant number:         Test point: 
pre  
 
Please mark on each line at the point which most accurately reflects your level of 
agreement AT THE MOMENT with the below statement: 
 
1. I feel alert 
STRONGLY  
AGREE 
 STRONGLY  
DISAGREE 
 
2. I feel that I will be able to perform the attention tasks to the best of my ability 
STRONGLY 
 AGREE 
 STRONGLY  
DISAGREE 
 
3.I do not feel that my driving would be impaired right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
 
4.I feel capable of driving safely right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
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Visual Analogue Scales of Subjective Drug Effects 
 
Participant number:         Test point: 
pre  
 
Please mark on each line at the point which most accurately reflects your level of 
agreement AT THE MOMENT with the below statement: 
 
1. Strength of drug effect 
NO EFFECT 
 
 VERY STRONG 
EFFECT 
2. Liking of the drug effect 
DISLIKE VERY 
MUCH 
 
 LIKE VERY 
MUCH 
3. Alert level 
NOT ALERT 
 
 VERY ALERT 
4. Intoxication 
NOT 
INTOXICATED 
 
 VERY 
INTOXICATED 
 
 
 
 
   
 
 
